Fresh analysis indicates that individuals who discontinue new slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who stop conventional diet and exercise regimens.
Research printed in a leading health publication points out that while obese individuals frequently drop a large proportion of their total mass while using the jabs, the mass returns at an estimated rate of nearly a kilo each month once they quit.
"Users purchasing these drugs should be aware of the potential of quick weight regain when the medication is stopped," stated expert Dr. Susan Jebb.
This pace of regain suggests a return to starting weight in about a year and a half.
Comparing Treatments
The research, which reviewed 37 of trials involving over 9,000 of patients, compared the results of these new drugs with other pills.
The team point out that individuals who shed pounds through dieting usually see a slower weight regain—approximately 100 grams monthly—post-intervention.
Explaining the Quick Regain
Doctors propose the way of the drugs accounts for the accelerated rebound.
The injections mimic a natural hormone called GLP-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations far above than normal could lead to the system to produce less of its endogenous hormone, and could lessen responsiveness to its effects," said Dr. Adam Collins, a nutrition expert.
"Discontinuation of this GLP-1 'fix' results in hunger is uncontrolled, making overeating a significant risk."
A Lifelong Disease?
Health authorities advise the injections for individuals with weight-linked health risks, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the significant potential of weight regain, the treatment might need to be life-long.
This perspective is supported by drug manufacturers, who state that the results "emphasize the persistent character of excess weight," comparing it to managing conditions like diabetes.
User Testimonies
People who have stopped the jabs report a sudden resurgence of hunger.
"It felt as if a switch flipping and you're instantly starving," described one woman.
This challenge is compounded if users have not developed permanent lifestyle or habit changes during treatment.
Widespread Use
Figures show that millions of adults in the UK have tried weight-loss jabs in the past year, with interest remaining high.
- Use is higher among women than men.
- The 40s and 50s demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers stress that while GLP-1 drugs are powerful tools for weight loss, they are not a standalone cure and lasting health benefits relies on integrated lifestyle management.
